Compare · AXGN vs ECOR
AXGN vs ECOR
Side-by-side comparison of Axogen Inc. (AXGN) and electroCore Inc. (ECOR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AXGN and ECOR operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- AXGN is the larger of the two at $2.09B, about 27.8x ECOR ($75.3M).
- AXGN has been more active in the news (6 items in the past 4 weeks vs 1 for ECOR).
- AXGN has more recent analyst coverage (11 ratings vs 2 for ECOR).
- Company
- Axogen Inc.
- electroCore Inc.
- Price
- -
- -
- Market cap
- $2.09B
- $75.3M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- News (4w)
- 6
- 1
- Recent ratings
- 11
- 2
Axogen Inc.
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
electroCore Inc.
electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld delivery system for multi-year use prescribed on a monthly basis. The company was founded in 2005 and is headquartered in Rockaway, New Jersey.
Latest AXGN
- Axogen, Inc. to Report Third Quarter 2026 Financial Results on October 28, 2026
- BofA Securities initiated coverage on AxoGen with a new price target
- Barclays initiated coverage on AxoGen with a new price target
- Nasdaq Hits Fresh Ground on Chip and Software Strength as Dow, Small Caps Lag for the Week
- Axogen Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair
- SEC Form 424B5 filed by Axogen Inc.
- Amendment: Axogen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Axogen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Axogen Announces Pricing of $208.7 Million Public Offering of Common Stock
Latest ECOR
- Director Errico Thomas J. bought $49,082 worth of shares (5,000 units at $9.82), increasing direct ownership by 1% to 363,904 units (SEC Form 4)
- Amendment: Officer Fox Michael bought $49,004 worth of shares (5,000 units at $9.80), increasing direct ownership by 4% to 130,000 units (SEC Form 4)
- Officer Fox Michael was granted 5,000 shares, increasing direct ownership by 4% to 130,000 units (SEC Form 4)
- Director Theofilos James Charles was granted 11,123 shares, increasing direct ownership by 47% to 34,670 units (SEC Form 4)
- Director Goldstein Julie Ann was granted 11,123 shares, increasing direct ownership by 11% to 112,510 units (SEC Form 4)
- Director Wilber Patricia was granted 11,123 shares, increasing direct ownership by 15% to 83,448 units (SEC Form 4)
- Director Errico Thomas J. was granted 15,572 shares, increasing direct ownership by 5% to 358,904 units (SEC Form 4)
- Director Bonfiglioli Elena was granted 11,123 shares, increasing direct ownership by 36% to 41,672 units (SEC Form 4)
- Officer Fox Michael was granted 55,000 shares, increasing direct ownership by 79% to 125,000 units (SEC Form 4)
- Officer Lev Joshua S. was granted 55,000 shares, increasing direct ownership by 65% to 139,889 units (SEC Form 4)